WO2010141093A3 - Co-signaling methods for treating cancers - Google Patents

Co-signaling methods for treating cancers Download PDF

Info

Publication number
WO2010141093A3
WO2010141093A3 PCT/US2010/001625 US2010001625W WO2010141093A3 WO 2010141093 A3 WO2010141093 A3 WO 2010141093A3 US 2010001625 W US2010001625 W US 2010001625W WO 2010141093 A3 WO2010141093 A3 WO 2010141093A3
Authority
WO
WIPO (PCT)
Prior art keywords
individual
lymphocytes
administering
neoplastic disease
treating cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/001625
Other languages
French (fr)
Other versions
WO2010141093A2 (en
Inventor
Scott E. Strome
Dan H. Schulze
Andrei Chapoval
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland, Baltimore
University of Maryland, College Park
Original Assignee
University of Maryland, Baltimore
University of Maryland, College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland, Baltimore, University of Maryland, College Park filed Critical University of Maryland, Baltimore
Publication of WO2010141093A2 publication Critical patent/WO2010141093A2/en
Publication of WO2010141093A3 publication Critical patent/WO2010141093A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided herein is a method of treating a neoplastic disease in an individual in need of such treatment, comprising the steps of: expanding γδ T lymphocytes in vitro; priming Natural Kill cells in vitro; and administering said expanded γδ T lymphocytes and said primed Natural Kill cells to said individual, thereby resulting in a cytotoxic or cytolytic effect. Further provided is a method of treating a neoplastic disease in an individual in need of such treatment, comprising the steps of: administering a compound to said individual that activates yδ T lymphocytes; and administering an antibody directed against a tumor antigen associated with said neoplastic disease.
PCT/US2010/001625 2009-06-04 2010-06-04 Co-signaling methods for treating cancers Ceased WO2010141093A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18400009P 2009-06-04 2009-06-04
US61/184,000 2009-06-04

Publications (2)

Publication Number Publication Date
WO2010141093A2 WO2010141093A2 (en) 2010-12-09
WO2010141093A3 true WO2010141093A3 (en) 2011-04-21

Family

ID=43298366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001625 Ceased WO2010141093A2 (en) 2009-06-04 2010-06-04 Co-signaling methods for treating cancers

Country Status (1)

Country Link
WO (1) WO2010141093A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2666466A4 (en) * 2011-01-21 2014-11-05 Biotherapy Inst Of Japan PROCESS FOR THE PRODUCTION OF BLOOD PREPARATION ENRICHED IN NK CELLS
EP2852409B1 (en) * 2012-05-23 2020-03-25 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN102899289B (en) * 2012-10-24 2014-09-03 扬州维克斯生物科技有限公司 Method for preparing super cytokine induced killer (CIK) cells
IL282953B2 (en) 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015039100A1 (en) * 2013-09-16 2015-03-19 The Trustees Of The University Of Pennsylvania Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
CN109517793B (en) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 Establishment method for NK cell and gamma delta T cell co-culture
WO2020143042A1 (en) * 2019-01-11 2020-07-16 深圳市双科生物科技有限公司 Method for restoring cell function
CN110283785A (en) * 2019-05-16 2019-09-27 安徽瑞达健康产业有限公司 A kind of method that gamma delta T-NK cell co-cultures

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US20050164306A1 (en) * 2002-04-19 2005-07-28 Adrien Beaudoin Methods for screening for a compound useful in the treatment or prevention of lymphocytic disorders, for inhibiting lymphocite activity and preventing or treating lymphocytic disorders
US20080199475A1 (en) * 2006-11-27 2008-08-21 Patrys Limited Novel glycosylated peptide target in neoplastic cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US20050164306A1 (en) * 2002-04-19 2005-07-28 Adrien Beaudoin Methods for screening for a compound useful in the treatment or prevention of lymphocytic disorders, for inhibiting lymphocite activity and preventing or treating lymphocytic disorders
US20080199475A1 (en) * 2006-11-27 2008-08-21 Patrys Limited Novel glycosylated peptide target in neoplastic cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALEXANDER A.A. ET AL: "Isopentenyl pyrophosphate-activated CD56+{gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma", CLIN CANCER RES., vol. 14, no. 13, July 2008 (2008-07-01), pages 4232 - 4240 *

Also Published As

Publication number Publication date
WO2010141093A2 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
BR112019009925A2 (en) method for preparing remnant tumor infiltrating lymphocytes for adoptive t-cell therapy, and method for treating a cancer.
DOP2017000177A (en) NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT
WO2011053750A3 (en) Drug resistant immunotherapy for treatment of a cancer
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX2018010586A (en) STING ACTIVATION NANOVACUNA FOR IMMUNOTHERAPY.
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
MX2011007589A (en) Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody.
PE20141937A1 (en) METHODS TO TREAT DISORDERS RELATED TO MUTANT VIII OF ELIMINATION OF EPIDERMAL GROWTH FACTOR
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
MY161724A (en) Therapeutic canine immunoglobulins and methods of using the same
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
MX2012012668A (en) High shear application in drug delivery.
HK1200716A1 (en) Method for treating cancer using an oral preparation of a cytidine analog
WO2007016130A3 (en) A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
WO2017076360A8 (en) Combination therapy for malignant diseases
WO2013104050A3 (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
MX2019015194A (en) COMPOSITIONS AND METHODS FOR CANCER THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS.
PH12017500478A1 (en) Immunogenic/therapeutic glycoconjugate compositions and uses thereof
CY1115803T1 (en) MEASURES AND METHODS OF ACTION OF CELLULAR IMMUNE TREATMENT AGAINST CANCER USING VULNERABLE VOLUME KNOWLEDGE CELLS
WO2022229884A3 (en) Recombinant antigen presenting cells
WO2015157299A3 (en) Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells
JP2019517507A5 (en)
WO2007149586A3 (en) Anti-c35 antibodies for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10783712

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10783712

Country of ref document: EP

Kind code of ref document: A2